Index
RUT
Market Cap
1.76B
Enterprise Value
1.66B
Income
-102.66M
Sales
81.26M
Book/sh
2.22
Cash/sh
4.96
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
264
IPO
Apr 28, 2017
P/E
-
Forward P/E
51.90
PEG
0.75
P/S
21.68
P/B
10.78
P/C
4.83
P/FCF
-
EV/EBITDA
-
EV/Sales
20.44
Quick Ratio
10.82
Current Ratio
10.82
Debt/Eq
1.61
LT Debt/Eq
1.59
Option/Short
Yes / Yes
EPS (ttm)
-1.37
EPS next Y
0.46
EPS next Q
-0.43
EPS this Y
226.55%
EPS next Y
-66.24%
EPS next 5Y
69.06%
EPS past 3/5Y
- 21.35%
Sales past 3/5Y
-36.43% 22.16%
EPS Y/Y TTM
8.99%
Sales Y/Y TTM
-12.98%
EPS Q/Q
-95.19%
Sales Q/Q
-91.12%
Insider Own
4.30%
Insider Trans
-4.25%
Inst Own
98.18%
Inst Trans
-2.95%
ROA
-22.72%
ROE
-42.02%
ROIC
-24.22%
Gross Margin
87.28%
Oper. Margin
-140.35%
Profit Margin
-126.33%
SMA20
1.19%
SMA50
-4.74%
SMA200
3.74%
Trades
Shs Outstand
73.10M
Shs Float
70.41M
52W High
29.75 -19.50%
52W Low
11.51 108.07%
Volatility
3.90% 3.81%
ATR (14)
1.07
RSI (14)
49.07
Beta
1.14
Rel Volume
1.60
Avg Volume
656.24K
Volume
633,908
Perf Week
2.96%
Perf Month
-6.01%
Perf Quarter
-0.96%
Perf Half Y
-10.84%
Perf YTD
-9.04%
Perf Year
92.05%
Perf 3Y
180.43%
Perf 5Y
-33.27%
Perf 10Y
-
Prev Close
24.15
Price
23.95
Change
-0.83%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-09-26 Resumed Truist
Buy
$28
Dec-12-25 Upgrade Wells Fargo
Equal Weight → Overweight
$33
Dec-03-25 Initiated Citizens JMP
Mkt Outperform
$32
Oct-24-25 Resumed Wells Fargo
Equal Weight
$15
Oct-14-25 Upgrade H.C. Wainwright
Neutral → Buy
$26
Oct-10-25 Initiated B. Riley Securities
Buy
$30
May-20-25 Initiated TD Cowen
Buy
Dec-16-24 Upgrade JP Morgan
Neutral → Overweight
$18
Nov-07-24 Upgrade Leerink Partners
Market Perform → Outperform
$10 → $25
Nov-01-24 Downgrade Wells Fargo
Overweight → Equal Weight
$12
Mar-21-23 Resumed Wells Fargo
Overweight
$12
Jan-04-23 Reiterated H.C. Wainwright
Neutral
$10 → $8
Dec-20-22 Upgrade Jefferies
Hold → Buy
$7.70 → $11
Nov-01-22 Downgrade H.C. Wainwright
Buy → Neutral
$40 → $8
Oct-21-22 Downgrade SVB Leerink
Outperform → Mkt Perform
$8
Oct-04-22 Resumed Wells Fargo
Overweight
$45 → $9
May-05-22 Upgrade Guggenheim
Neutral → Buy
$14
Mar-15-22 Initiated Evercore ISI
Outperform
$15
Dec-10-21 Upgrade SVB Leerink
Mkt Perform → Outperform
Nov-17-21 Resumed Guggenheim
Neutral
Show Previous Ratings
Today 08:44AM
07:26AM
06:00AM
04:42AM
Jun-18-26 08:00AM
06:05PM
Loading…
Jun-14-26 06:05PM
May-14-26 04:05PM
May-13-26 06:00AM
May-08-26 08:30AM
May-07-26 04:05PM
Apr-21-26 05:30PM
Apr-17-26 03:00PM
Apr-16-26 06:00AM
Apr-09-26 06:00AM
Apr-01-26 06:00AM
06:00AM
Loading…
Mar-30-26 06:00AM
Mar-24-26 06:00AM
Mar-18-26 07:46AM
Mar-17-26 05:02PM
Mar-02-26 04:01PM
10:37AM
08:30AM
07:15AM
06:01AM
06:00AM
Feb-25-26 12:15PM
Feb-12-26 06:00AM
Jan-27-26 06:00AM
Jan-12-26 06:00AM
Jan-11-26 06:00PM
12:19PM
Loading…
Jan-09-26 12:19PM
Jan-06-26 01:34PM
Dec-03-25 09:35AM
Dec-02-25 04:05PM
Nov-24-25 06:00AM
Nov-18-25 12:16PM
03:38AM
01:01AM
01:00AM
Nov-17-25 04:13PM
(The Wall Street Journal)
+29.05%
09:35AM
(The Wall Street Journal)
09:02AM
(Investor's Business Daily)
08:10AM
06:00AM
Nov-06-25 05:35PM
04:05PM
Nov-04-25 10:00AM
Oct-30-25 10:00AM
Oct-29-25 12:00PM
Oct-28-25 06:00AM
Oct-23-25 12:30PM
Oct-16-25 09:55AM
06:00AM
Oct-15-25 09:11AM
Oct-14-25 12:00PM
Oct-13-25 04:00PM
Oct-10-25 03:20PM
(Investor's Business Daily)
+6.74%
09:36AM
Oct-09-25 08:30AM
06:00AM
Sep-02-25 12:30PM
06:00AM
Aug-19-25 06:00AM
Aug-14-25 11:41AM
Aug-12-25 10:26AM
09:55AM
Aug-11-25 06:00AM
Aug-07-25 06:35PM
04:05PM
Jul-29-25 11:03AM
Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More
(GlobeNewswire)
Jul-28-25 06:00AM
Jul-18-25 09:58AM
Jul-17-25 06:00AM
Jul-10-25 12:00PM
Jun-20-25 12:00PM
Jun-04-25 09:55AM
May-30-25 06:00AM
May-22-25 05:00PM
May-21-25 06:00AM
May-19-25 04:15PM
May-14-25 09:55AM
May-08-25 05:50PM
04:05PM
May-07-25 10:35AM
Apr-30-25 06:33PM
Apr-28-25 05:33PM
10:48AM
Apr-25-25 01:00PM
Apr-21-25 06:00AM
Apr-17-25 06:00AM
Apr-09-25 10:13AM
Apr-05-25 11:00AM
Mar-26-25 06:00AM
Mar-25-25 04:30PM
10:49AM
Mar-05-25 04:05PM
Mar-04-25 07:09AM
Feb-26-25 06:00AM
Feb-25-25 06:00AM
Feb-18-25 06:00AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Chairman of the Board Mr. Kenneth H. Galbraith C.A.
Chief Scientific Officer Dr. Paul A. Moore Ph.D.
Executive VP & Chief Business Officer Mr. Scott Platshon
Executive VP & Chief Operating Officer Mr. Mark Hollywood
VP of Investor Relations Ms. Shrinal Inamdar
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jeffrey T L Smith Former Officer Mar 06 '26 Proposed Sale 24.80 247,333 6,133,858 Mar 06 09:00 PM Leone D Patterson Former officer Feb 17 '26 Proposed Sale 22.60 31,641 715,087 Feb 17 09:00 PM Leone D Patterson Former officer Feb 13 '26 Proposed Sale 23.17 128,548 2,978,457 Feb 13 09:00 PM Hollywood Mark EVP & Chief Operating Officer Jan 12 '26 Option Exercise 0.00 17,666 0 139,033 Jan 13 05:11 PM Hollywood Mark EVP & Chief Operating Officer Jan 12 '26 Sale 22.67 6,120 138,762 132,913 Jan 13 05:11 PM Smith Jeffrey T L EVP & Chief Medical Officer Jan 12 '26 Option Exercise 0.00 17,666 0 36,018 Jan 12 09:00 PM Smith Jeffrey T L EVP & Chief Medical Officer Jan 12 '26 Sale 22.67 9,310 211,090 26,708 Jan 12 09:00 PM Moore Paul Andrew Chief Scientific Officer Jan 12 '26 Option Exercise 0.00 17,666 0 58,057 Jan 12 08:32 PM Moore Paul Andrew Chief Scientific Officer Jan 12 '26 Sale 22.67 9,560 216,759 48,497 Jan 12 08:32 PM Galbraith Kenneth Chair & CEO Jan 12 '26 Option Exercise 0.00 64,000 0 257,266 Jan 12 07:07 PM Galbraith Kenneth Chair & CEO Jan 12 '26 Sale 22.67 30,424 689,819 226,842 Jan 12 07:07 PM Leone D Patterson Former officer Jan 12 '26 Proposed Sale 23.17 6,832 158,297 Jan 12 05:00 PM Kenneth Galbraith Officer Jan 12 '26 Proposed Sale 23.17 30,424 704,924 Jan 12 05:00 PM Paul Andrew Moore Officer Jan 12 '26 Proposed Sale 23.17 9,560 221,505 Jan 12 05:00 PM Jeffrey T L Smith Officer Jan 12 '26 Proposed Sale 23.17 9,310 215,713 Jan 12 05:00 PM Mark Hollywood Officer Jan 12 '26 Proposed Sale 23.17 6,120 141,800 Jan 12 05:00 PM Smith Jeffrey T L EVP & Chief Medical Officer Jan 05 '26 Option Exercise 0.00 20,000 0 28,890 Jan 05 08:22 PM Smith Jeffrey T L EVP & Chief Medical Officer Jan 05 '26 Sale 25.10 10,538 264,471 18,352 Jan 05 08:22 PM Galbraith Kenneth Chair & CEO Jan 05 '26 Option Exercise 0.00 114,334 0 224,952 Jan 05 08:20 PM Galbraith Kenneth Chair & CEO Jan 05 '26 Sale 25.10 54,343 1,363,841 158,286 Jan 05 08:20 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '26 Option Exercise 0.00 37,168 0 51,212 Jan 05 08:18 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '26 Sale 25.10 20,110 504,699 31,212 Jan 05 08:18 PM Smith Jeffrey T L Officer Jan 05 '26 Proposed Sale 26.62 10,538 280,522 Jan 05 07:00 PM Kenneth Galbraith Officer Jan 05 '26 Proposed Sale 26.62 54,343 1,446,611 Jan 05 07:00 PM Paul Andrew Moore Officer Jan 05 '26 Proposed Sale 26.62 20,110 535,328 Jan 05 07:00 PM Galbraith Kenneth Chair & CEO Dec 22 '25 Option Exercise 0.00 100,000 0 180,803 Dec 22 05:52 PM Galbraith Kenneth Chair & CEO Dec 22 '25 Sale 27.02 47,528 1,284,311 133,275 Dec 22 05:52 PM Galbraith, Kenneth Officer Dec 22 '25 Proposed Sale 27.23 47,528 1,294,187 Dec 22 05:00 PM Derek John Michael Miller Former Director Nov 24 '25 Proposed Sale 23.82 118,000 2,810,760 Nov 24 08:00 PM Neil Gallagher Former Director Nov 21 '25 Proposed Sale 23.82 105,000 2,501,100 Nov 21 08:00 PM
